 | • レポートコード：QYR2104Z4086 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、神経皮膚障害のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（結節性硬化症（TS）、神経線維腫症（NF）、スタージーウェーバー症候群、フォンヒッペルリンドウ（VHL）、運動失調-毛細血管拡張性運動失調症（A-T）、その他）、用途別市場規模（病院、診療所、診断センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・神経皮膚障害の市場動向 ・企業の競争状況、市場シェア ・神経皮膚障害の種類別市場規模（結節性硬化症（TS）、神経線維腫症（NF）、スタージーウェーバー症候群、フォンヒッペルリンドウ（VHL）、運動失調-毛細血管拡張性運動失調症（A-T）、その他） ・神経皮膚障害の用途別市場規模（病院、診療所、診断センター、その他） ・神経皮膚障害の北米市場規模2016-2027（アメリカ、カナダ） ・神経皮膚障害のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経皮膚障害のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経皮膚障害の中南米市場規模2016-2027（メキシコ、ブラジル） ・神経皮膚障害の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Johnson & Johnson、Medtronic、Abbott、Novartis、Roche、Sanofi、Takeda、Allergan、Syneron Medical、Aleva Neurotherapeutics、Abbott Laboratories、Bausch Health） ・結論 |
The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord. These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late.
The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers.
Market Analysis and Insights: Global Neurocutaneous Disorder Market
The global Neurocutaneous Disorder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurocutaneous Disorder market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurocutaneous Disorder market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurocutaneous Disorder market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurocutaneous Disorder market.
Global Neurocutaneous Disorder Scope and Market Size
Neurocutaneous Disorder market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurocutaneous Disorder market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Tuberous Sclerosis (TS)
Neurofibromatosis (NF)
Sturge-Weber Syndrome
Von Hippel-Lindau (VHL)
Ataxia-Telangiectasia (A-T)
Others
Segment by Application
Hospitals
Clinics
Diagnostic Centers
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Johnson & Johnson
Medtronic
Abbott
Novartis
Roche
Sanofi
Takeda
Allergan
Abbott
Novartis
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurocutaneous Disorder Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tuberous Sclerosis (TS)
1.2.3 Neurofibromatosis (NF)
1.2.4 Sturge-Weber Syndrome
1.2.5 Von Hippel-Lindau (VHL)
1.2.6 Ataxia-Telangiectasia (A-T)
1.2.7 Others
1.3 Market by Application
1.3.1 Global Neurocutaneous Disorder Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurocutaneous Disorder Market Perspective (2016-2027)
2.2 Neurocutaneous Disorder Growth Trends by Regions
2.2.1 Neurocutaneous Disorder Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurocutaneous Disorder Historic Market Share by Regions (2016-2021)
2.2.3 Neurocutaneous Disorder Forecasted Market Size by Regions (2022-2027)
2.3 Neurocutaneous Disorder Industry Dynamic
2.3.1 Neurocutaneous Disorder Market Trends
2.3.2 Neurocutaneous Disorder Market Drivers
2.3.3 Neurocutaneous Disorder Market Challenges
2.3.4 Neurocutaneous Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurocutaneous Disorder Players by Revenue
3.1.1 Global Top Neurocutaneous Disorder Players by Revenue (2016-2021)
3.1.2 Global Neurocutaneous Disorder Revenue Market Share by Players (2016-2021)
3.2 Global Neurocutaneous Disorder Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurocutaneous Disorder Revenue
3.4 Global Neurocutaneous Disorder Market Concentration Ratio
3.4.1 Global Neurocutaneous Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurocutaneous Disorder Revenue in 2020
3.5 Neurocutaneous Disorder Key Players Head office and Area Served
3.6 Key Players Neurocutaneous Disorder Product Solution and Service
3.7 Date of Enter into Neurocutaneous Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurocutaneous Disorder Breakdown Data by Type
4.1 Global Neurocutaneous Disorder Historic Market Size by Type (2016-2021)
4.2 Global Neurocutaneous Disorder Forecasted Market Size by Type (2022-2027)
5 Neurocutaneous Disorder Breakdown Data by Application
5.1 Global Neurocutaneous Disorder Historic Market Size by Application (2016-2021)
5.2 Global Neurocutaneous Disorder Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neurocutaneous Disorder Market Size (2016-2027)
6.2 North America Neurocutaneous Disorder Market Size by Type
6.2.1 North America Neurocutaneous Disorder Market Size by Type (2016-2021)
6.2.2 North America Neurocutaneous Disorder Market Size by Type (2022-2027)
6.2.3 North America Neurocutaneous Disorder Market Size by Type (2016-2027)
6.3 North America Neurocutaneous Disorder Market Size by Application
6.3.1 North America Neurocutaneous Disorder Market Size by Application (2016-2021)
6.3.2 North America Neurocutaneous Disorder Market Size by Application (2022-2027)
6.3.3 North America Neurocutaneous Disorder Market Size by Application (2016-2027)
6.4 North America Neurocutaneous Disorder Market Size by Country
6.4.1 North America Neurocutaneous Disorder Market Size by Country (2016-2021)
6.4.2 North America Neurocutaneous Disorder Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Neurocutaneous Disorder Market Size (2016-2027)
7.2 Europe Neurocutaneous Disorder Market Size by Type
7.2.1 Europe Neurocutaneous Disorder Market Size by Type (2016-2021)
7.2.2 Europe Neurocutaneous Disorder Market Size by Type (2022-2027)
7.2.3 Europe Neurocutaneous Disorder Market Size by Type (2016-2027)
7.3 Europe Neurocutaneous Disorder Market Size by Application
7.3.1 Europe Neurocutaneous Disorder Market Size by Application (2016-2021)
7.3.2 Europe Neurocutaneous Disorder Market Size by Application (2022-2027)
7.3.3 Europe Neurocutaneous Disorder Market Size by Application (2016-2027)
7.4 Europe Neurocutaneous Disorder Market Size by Country
7.4.1 Europe Neurocutaneous Disorder Market Size by Country (2016-2021)
7.4.2 Europe Neurocutaneous Disorder Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neurocutaneous Disorder Market Size (2016-2027)
8.2 Asia-Pacific Neurocutaneous Disorder Market Size by Type
8.2.1 Asia-Pacific Neurocutaneous Disorder Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurocutaneous Disorder Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurocutaneous Disorder Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurocutaneous Disorder Market Size by Application
8.3.1 Asia-Pacific Neurocutaneous Disorder Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurocutaneous Disorder Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurocutaneous Disorder Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurocutaneous Disorder Market Size by Region
8.4.1 Asia-Pacific Neurocutaneous Disorder Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurocutaneous Disorder Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurocutaneous Disorder Market Size (2016-2027)
9.2 Latin America Neurocutaneous Disorder Market Size by Type
9.2.1 Latin America Neurocutaneous Disorder Market Size by Type (2016-2021)
9.2.2 Latin America Neurocutaneous Disorder Market Size by Type (2022-2027)
9.2.3 Latin America Neurocutaneous Disorder Market Size by Type (2016-2027)
9.3 Latin America Neurocutaneous Disorder Market Size by Application
9.3.1 Latin America Neurocutaneous Disorder Market Size by Application (2016-2021)
9.3.2 Latin America Neurocutaneous Disorder Market Size by Application (2022-2027)
9.3.3 Latin America Neurocutaneous Disorder Market Size by Application (2016-2027)
9.4 Latin America Neurocutaneous Disorder Market Size by Country
9.4.1 Latin America Neurocutaneous Disorder Market Size by Country (2016-2021)
9.4.2 Latin America Neurocutaneous Disorder Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurocutaneous Disorder Market Size (2016-2027)
10.2 Middle East & Africa Neurocutaneous Disorder Market Size by Type
10.2.1 Middle East & Africa Neurocutaneous Disorder Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurocutaneous Disorder Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurocutaneous Disorder Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurocutaneous Disorder Market Size by Application
10.3.1 Middle East & Africa Neurocutaneous Disorder Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurocutaneous Disorder Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurocutaneous Disorder Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurocutaneous Disorder Market Size by Country
10.4.1 Middle East & Africa Neurocutaneous Disorder Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurocutaneous Disorder Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neurocutaneous Disorder Introduction
11.1.4 Pfizer Revenue in Neurocutaneous Disorder Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Neurocutaneous Disorder Introduction
11.2.4 Johnson & Johnson Revenue in Neurocutaneous Disorder Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Medtronic
11.3.1 Medtronic Company Details
11.3.2 Medtronic Business Overview
11.3.3 Medtronic Neurocutaneous Disorder Introduction
11.3.4 Medtronic Revenue in Neurocutaneous Disorder Business (2016-2021)
11.3.5 Medtronic Recent Development
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Abbott Business Overview
11.4.3 Abbott Neurocutaneous Disorder Introduction
11.4.4 Abbott Revenue in Neurocutaneous Disorder Business (2016-2021)
11.4.5 Abbott Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Neurocutaneous Disorder Introduction
11.5.4 Novartis Revenue in Neurocutaneous Disorder Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Neurocutaneous Disorder Introduction
11.6.4 Roche Revenue in Neurocutaneous Disorder Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Neurocutaneous Disorder Introduction
11.7.4 Sanofi Revenue in Neurocutaneous Disorder Business (2016-2021)
11.7.5 Sanofi Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Neurocutaneous Disorder Introduction
11.8.4 Takeda Revenue in Neurocutaneous Disorder Business (2016-2021)
11.8.5 Takeda Recent Development
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Neurocutaneous Disorder Introduction
11.9.4 Allergan Revenue in Neurocutaneous Disorder Business (2016-2021)
11.9.5 Allergan Recent Development
11.10 Syneron Medical
11.10.1 Syneron Medical Company Details
11.10.2 Syneron Medical Business Overview
11.10.3 Syneron Medical Neurocutaneous Disorder Introduction
11.10.4 Syneron Medical Revenue in Neurocutaneous Disorder Business (2016-2021)
11.10.5 Syneron Medical Recent Development
11.11 Aleva Neurotherapeutics
11.11.1 Aleva Neurotherapeutics Company Details
11.11.2 Aleva Neurotherapeutics Business Overview
11.11.3 Aleva Neurotherapeutics Neurocutaneous Disorder Introduction
11.11.4 Aleva Neurotherapeutics Revenue in Neurocutaneous Disorder Business (2016-2021)
11.11.5 Aleva Neurotherapeutics Recent Development
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Details
11.12.2 Abbott Laboratories Business Overview
11.12.3 Abbott Laboratories Neurocutaneous Disorder Introduction
11.12.4 Abbott Laboratories Revenue in Neurocutaneous Disorder Business (2016-2021)
11.12.5 Abbott Laboratories Recent Development
11.13 Bausch Health
11.13.1 Bausch Health Company Details
11.13.2 Bausch Health Business Overview
11.13.3 Bausch Health Neurocutaneous Disorder Introduction
11.13.4 Bausch Health Revenue in Neurocutaneous Disorder Business (2016-2021)
11.13.5 Bausch Health Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Neurocutaneous Disorder Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tuberous Sclerosis (TS)
Table 3. Key Players of Neurofibromatosis (NF)
Table 4. Key Players of Sturge-Weber Syndrome
Table 5. Key Players of Von Hippel-Lindau (VHL)
Table 6. Key Players of Ataxia-Telangiectasia (A-T)
Table 7. Key Players of Others
Table 8. Global Neurocutaneous Disorder Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neurocutaneous Disorder Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Neurocutaneous Disorder Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Neurocutaneous Disorder Market Share by Regions (2016-2021)
Table 12. Global Neurocutaneous Disorder Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Neurocutaneous Disorder Market Share by Regions (2022-2027)
Table 14. Neurocutaneous Disorder Market Trends
Table 15. Neurocutaneous Disorder Market Drivers
Table 16. Neurocutaneous Disorder Market Challenges
Table 17. Neurocutaneous Disorder Market Restraints
Table 18. Global Neurocutaneous Disorder Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Neurocutaneous Disorder Market Share by Players (2016-2021)
Table 20. Global Top Neurocutaneous Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurocutaneous Disorder as of 2020)
Table 21. Ranking of Global Top Neurocutaneous Disorder Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Neurocutaneous Disorder Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Neurocutaneous Disorder Product Solution and Service
Table 25. Date of Enter into Neurocutaneous Disorder Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Neurocutaneous Disorder Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Neurocutaneous Disorder Revenue Market Share by Type (2016-2021)
Table 29. Global Neurocutaneous Disorder Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Neurocutaneous Disorder Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Neurocutaneous Disorder Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Neurocutaneous Disorder Revenue Market Share by Application (2016-2021)
Table 33. Global Neurocutaneous Disorder Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Neurocutaneous Disorder Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Neurocutaneous Disorder Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Neurocutaneous Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Neurocutaneous Disorder Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Neurocutaneous Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Neurocutaneous Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Neurocutaneous Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Neurocutaneous Disorder Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Neurocutaneous Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Neurocutaneous Disorder Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Neurocutaneous Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Neurocutaneous Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Neurocutaneous Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neurocutaneous Disorder Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Neurocutaneous Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Neurocutaneous Disorder Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Neurocutaneous Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Neurocutaneous Disorder Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Neurocutaneous Disorder Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Neurocutaneous Disorder Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Neurocutaneous Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Neurocutaneous Disorder Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Neurocutaneous Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Neurocutaneous Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Neurocutaneous Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neurocutaneous Disorder Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Neurocutaneous Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Neurocutaneous Disorder Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Neurocutaneous Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Neurocutaneous Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Neurocutaneous Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Neurocutaneous Disorder Product
Table 68. Pfizer Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 69. Pfizer Recent Development
Table 70. Johnson & Johnson Company Details
Table 71. Johnson & Johnson Business Overview
Table 72. Johnson & Johnson Neurocutaneous Disorder Product
Table 73. Johnson & Johnson Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 74. Johnson & Johnson Recent Development
Table 75. Medtronic Company Details
Table 76. Medtronic Business Overview
Table 77. Medtronic Neurocutaneous Disorder Product
Table 78. Medtronic Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 79. Medtronic Recent Development
Table 80. Abbott Company Details
Table 81. Abbott Business Overview
Table 82. Abbott Neurocutaneous Disorder Product
Table 83. Abbott Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 84. Abbott Recent Development
Table 85. Novartis Company Details
Table 86. Novartis Business Overview
Table 87. Novartis Neurocutaneous Disorder Product
Table 88. Novartis Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 89. Novartis Recent Development
Table 90. Roche Company Details
Table 91. Roche Business Overview
Table 92. Roche Neurocutaneous Disorder Product
Table 93. Roche Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 94. Roche Recent Development
Table 95. Sanofi Company Details
Table 96. Sanofi Business Overview
Table 97. Sanofi Neurocutaneous Disorder Product
Table 98. Sanofi Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 99. Sanofi Recent Development
Table 100. Takeda Company Details
Table 101. Takeda Business Overview
Table 102. Takeda Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 103. Takeda Recent Development
Table 104. Allergan Company Details
Table 105. Allergan Business Overview
Table 106. Allergan Neurocutaneous Disorder Product
Table 107. Allergan Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 108. Allergan Recent Development
Table 109. Syneron Medical Company Details
Table 110. Syneron Medical Business Overview
Table 111. Syneron Medical Neurocutaneous Disorder Product
Table 112. Syneron Medical Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 113. Syneron Medical Recent Development
Table 114. Aleva Neurotherapeutics Company Details
Table 115. Aleva Neurotherapeutics Business Overview
Table 116. Aleva Neurotherapeutics Neurocutaneous Disorder Product
Table 117. Aleva Neurotherapeutics Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 118. Aleva Neurotherapeutics Recent Development
Table 119. Abbott Laboratories Company Details
Table 120. Abbott Laboratories Business Overview
Table 121. Abbott Laboratories Neurocutaneous Disorder Product
Table 122. Abbott Laboratories Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 123. Abbott Laboratories Recent Development
Table 124. Bausch Health Company Details
Table 125. Bausch Health Business Overview
Table 126. Bausch Health Neurocutaneous Disorder Product
Table 127. Bausch Health Revenue in Neurocutaneous Disorder Business (2016-2021) & (US$ Million)
Table 128. Bausch Health Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurocutaneous Disorder Market Share by Type: 2020 VS 2027
Figure 2. Tuberous Sclerosis (TS) Features
Figure 3. Neurofibromatosis (NF) Features
Figure 4. Sturge-Weber Syndrome Features
Figure 5. Von Hippel-Lindau (VHL) Features
Figure 6. Ataxia-Telangiectasia (A-T) Features
Figure 7. Others Features
Figure 8. Global Neurocutaneous Disorder Market Share by Application: 2020 VS 2027
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Diagnostic Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Neurocutaneous Disorder Report Years Considered
Figure 14. Global Neurocutaneous Disorder Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Neurocutaneous Disorder Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Neurocutaneous Disorder Market Share by Regions: 2020 VS 2027
Figure 17. Global Neurocutaneous Disorder Market Share by Regions (2022-2027)
Figure 18. Global Neurocutaneous Disorder Market Share by Players in 2020
Figure 19. Global Top Neurocutaneous Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurocutaneous Disorder as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Neurocutaneous Disorder Revenue in 2020
Figure 21. Global Neurocutaneous Disorder Revenue Market Share by Type (2016-2021)
Figure 22. Global Neurocutaneous Disorder Revenue Market Share by Type (2022-2027)
Figure 23. North America Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Neurocutaneous Disorder Market Share by Type (2016-2027)
Figure 25. North America Neurocutaneous Disorder Market Share by Application (2016-2027)
Figure 26. North America Neurocutaneous Disorder Market Share by Country (2016-2027)
Figure 27. United States Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Neurocutaneous Disorder Market Share by Type (2016-2027)
Figure 31. Europe Neurocutaneous Disorder Market Share by Application (2016-2027)
Figure 32. Europe Neurocutaneous Disorder Market Share by Country (2016-2027)
Figure 33. Germany Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Neurocutaneous Disorder Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Neurocutaneous Disorder Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Neurocutaneous Disorder Market Share by Region (2016-2027)
Figure 43. China Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Neurocutaneous Disorder Market Share by Type (2016-2027)
Figure 51. Latin America Neurocutaneous Disorder Market Share by Application (2016-2027)
Figure 52. Latin America Neurocutaneous Disorder Market Share by Country (2016-2027)
Figure 53. Mexico Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Neurocutaneous Disorder Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Neurocutaneous Disorder Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Neurocutaneous Disorder Market Share by Country (2016-2027)
Figure 59. Turkey Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Neurocutaneous Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Pfizer Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 63. Johnson & Johnson Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 64. Medtronic Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 65. Abbott Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 67. Roche Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 68. Sanofi Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 69. Takeda Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 70. Allergan Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 71. Syneron Medical Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 72. Aleva Neurotherapeutics Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 73. Abbott Laboratories Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 74. Bausch Health Revenue Growth Rate in Neurocutaneous Disorder Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界のスタージーウェーバー症候群（SWS）治療市場規模・現状・予測（2021年-2027年） Sturge-Weber syndrome or Sturge-Weber-Krabbe disease, sometimes referred to as encephalotrigeminal angiomatosis, is a rare congenital neurological and skin disorder. It is one of the phakomatoses and is often associated with port-wine stains of the face, glaucoma, seizures, mental retardation, and i…- 世界のうつ病性障害市場規模・現状・予測（2021年-2027年） Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including…
- 世界の耳鼻咽喉科疾患治療市場規模・現状・予測（2021年-2027年） ENT is a medical abbreviation for ears, nose and throat. Major factor contributing to growth of the global ENT disorder treatment market includes increasing pollution. Market Analysis and Insights: Global ENT Disorder Treatment Market The global ENT Disorder Treatment market size is projected to rea…
- 世界の季節性情動障害治療市場規模・現状・予測（2021年-2027年） Seasonal Affective Disorder is a type of depression that occurs during a certain time of the year. This disorder is related to changes in seasons, mostly occurs in winter but some people may have this disorder in summers as well. Seasonal affective disorder is most common in women, people between th…
- 世界の脂質障害治療市場規模・現状・予測（2021年-2027年） Lipid disorder means the people high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides,. Several biopharma companies are focusing on developing effective solutions for treating lipid disorders. Companies involved in lipid disorder treatment market include Teva Phar…